Costs of Treatment of Severe COPD Exacerbation in Serbia

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V. et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 380(9859), 2095-2128. DOI: 10.1016/S0140-6736(12)61728-0.10.1016/S0140-6736(12)61728-0Search in Google Scholar

2. Mathers CD, Loncar D. (2006). Projections of Global Mortality and Burden of Disease from 2002 to 2030. Plos Medicine. 3(11), 2011-2030. DOI:10.1371/journal. pmed.003044210.1371/journal.pmed.0030442Search in Google Scholar

3. Blasi F, Cesana G, Conti S, Chiodini V, Aliberti S, Fornari C & Mantovani LG. (2014). The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One. 9(6), 1-8. DOI:10.1371/journal.pone.010122810.1371/journal.pone.0101228407419024971791Search in Google Scholar

4. Wan E, DeMeo D, Hersh C, Shapiro S, Rosiello R, Sama S, Fuhlbrigge A, Foreman M & Silverman E. (2011). Clinical predictors of frequent exacerbations in subjects with 6 severe chronic obstructive pulmonary disease (COPD). Respir Med. 105(4), 588–594. DOI: 10.1016/j.rmed.2010.11.01510.1016/j.rmed.2010.11.015304631221145719Search in Google Scholar

5. Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF & Wedzicha JA. (2010). Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med. 363(12), 1128-1138. DOI:10.1056/NEJMoa0909883.10.1056/NEJMoa090988320843247Search in Google Scholar

6. Parikh R, Shah TG & Tandon R. (2016). COPD exacerbation care bundle improves standard of care, length of stay, and readmission rates. Int J Chron Obstruct Pulmon Dis. 11(1), 577-583. DOI: 10.2147/COPD.S100401.10.2147/COPD.S100401480115927042046Search in Google Scholar

7. Montserrat-Capdevila J, Godoy P, Marsal JR, Barbé F & Galvn L. (2015). Risk of exacerbation in chronic obstructive pulmonary disease: a primary care retrospective cohort study. BMC Fam Pract. 16:173. DOI: 10.1186/s12875-015-0387-610.1186/s12875-015-0387-6467252826642879Search in Google Scholar

8. Guarascio AJ, Ray SM, Finch CK & Self TH. (2013). The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 5, 235-245. DOI: 10.2147/CEOR.S3432110.2147/CEOR.S34321369480023818799Search in Google Scholar

9. Lazic Z, Gajovic O, Tanaskovic I, Milovanovic D, Atanasijevic D & Jakovljevic M. (2012). GOLD Stage Impact on COPD Direct Medical Costs in the Elderly. Health Behav & Pub Health. 2(3), 1-7.Search in Google Scholar

10. Menn P, Leidl R & Holle R. (2012). A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics. 30(9), 825-840. DOI: 10.2165/11591340-000000000-0000010.2165/11591340-000000000-0000022799876Search in Google Scholar

11. Hoogendoorn M, Kappelhoff BS, Overbeek JA, Wouters EF & Rutten-van Mölken MP. (2012). Which long-acting bronchodilator is most cost-effective for the treatment of COPD? Neth J Med. Review. 70(8), 357-364.Search in Google Scholar

12. Ornek T, Tor M, Altın R, Atalay F, Geredeli E, Soylu O & Erboy F. (2012). Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Int J Med Sci. 9(4), 285-90. DOI: 10.7150/ijms.403910.7150/ijms.4039337293422701335Search in Google Scholar

13. Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M & Blum S. (2011). Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 14(3), 315-323. DOI: 10.3111/13696998.2011.576295.10.3111/13696998.2011.57629521500975Search in Google Scholar

14. Abudagga A, Sun SX, Tan H & Solem CT. (2013). Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis. Int J Chron Obstruct Pulmon Dis. 8, 175-85. DOI: 10.2147/COPD.S40437.10.2147/COPD.S40437362496523589684Search in Google Scholar

15. Global Initiative for Chronic Obstructive Lung Disease. (2014). Global Strategy for the Diagnosis. Management and Prevention of Chronic Obstructive Pulmonary Disease. Available on: http://www.goldcopd.orgSearch in Google Scholar

16. World Health Organization. Chronic obstructive pulmonary disease (COPD).(2011). Available on: http://www.who.int/respiratory/copd/en/Search in Google Scholar

17. Valente S, Pasciuto G, Bernabei R & Corbo GM. (2010). Do we need different treatments for very elderly COPD patients? Respiration. 80(5), 357–368. DOI: 10.1159/000320221.10.1159/00032022120733280Search in Google Scholar

18. Hillas G, Perlikos F, Tsiligianni I & Tzanakis N. (2015). Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 10, 95-109. DOI: 10.2147/COPD. S54473.10.2147/COPDSearch in Google Scholar

19. Pasquale MK, Sun SX, Song F, Hartnett HJ & Stem-kowski SA. (2012). Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 7, 757-764. DOI: 10.2147/COPD.S36997.10.2147/COPD.S36997349653623152680Search in Google Scholar

20. Doos L, Uttley J, Onyia I, Iqbal Z, Jones PW & Kadam UT. (2014). Mosaic segmentation, COPD and CHF multimorbidity and hospital admission costs: a clinical linkage study. J Public Health (Oxf). 36(2), 317-324. DOI: 10.1093/pubmed/fdt070.10.1093/pubmed/fdt07023903003Search in Google Scholar

21. Halpin DM & Miravitlles M. (2006). Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 3(7), 619–623. DOI: 10.1513/pats.200603-093SS10.1513/pats.200603-093SS16963544Search in Google Scholar

22. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA & Coultas DB. (2000). Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med. 160(17), 2653–2658. DOI:10.1001/archinte.160.17.265310.1001/archinte.160.17.265310999980Search in Google Scholar

23. Cazzola M, Bettoncelli G, Sessa E, Cricelli C & Biscione G. (2010). Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 80(2), 112–119. DOI: 10.1159/00028188010.1159/00028188020134148Search in Google Scholar

24. Mannino DM1, Watt G, Hole D, Gillis C, Hart C, Mc-Connachie A, Davey Smith G, Upton M, Hawthorne V, Sin DD, Man SF, Van Eeden S, Mapel DW & Vestbo J. (2006). The natural history of chronic obstructive pulmonary disease. Eur Respir J. 27(3), 627–643. DOI: 10.1183/09031936.06.0002460510.1183/09031936.06.0002460516507865Search in Google Scholar

25. Säynäjäkangas O, Kinnunen T, Tuuponen T & Keistinen T. (2004). Length of stay and interval to readmission in emergency hospital treatment of COPD. Age Ageing. 33(6), 567-570. DOI: 10.1093/ageing/afh18810.1093/ageing/afh18815347536Search in Google Scholar

26. Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A & White PT. (2015). Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study. Int J Chron Obstruct Pulmon Dis. 10, 603-611. DOI: 10.2147/COPD. S77092.10.2147/COPDSearch in Google Scholar

27. Diamantea F, Kostikas K, Bartziokas K, Karakontaki F, Tsikrika S, Pouriki S, Polychronopoulos V, Karagiannidis N, Haniotou A & Papaioannou A. (2014). Prediction of hospitalization stay in COPD exacerbations: the AECOPD-F score. Respir Care. 59(11), 1679-1686. DOI: 10.4187/respcare.03171.10.4187/respcare.0317124962226Search in Google Scholar

28. Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S & Jameson K. (2012). Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis. 7, 183-199. DOI: 10.2147/COPD.S29820.10.2147/COPD.S29820332500022500119Search in Google Scholar